Meiji Holdings Co., Ltd. · TSE:2269
Meiji — Corporate Update (December 2018)
21 slides from Meiji's corporate update, Dec 10, 2018
Slide 1: Business Strategy of KM Biologics
Briefing on Pharmaceutical Segment Business Strategy of KM Biologics December 10, 2018
Slide 2: Agenda
Agenda 1. Company Profile of KM Biologics 2. Our Vision 3. Our Business Strategy 4. Outlook for FYE March 2019 Information in this material is not intended to solicit sale or purchase of shares in Meiji Holdings. Business forecasts and other forward-looking statements are based on information av
Slide 3: 1. Company Profile of KM Biologics
1. Company Profile of KM Biologics 3 ｜ 2018.12.10 ｜ Copyright © Meiji Holdings Co., Ltd. All rights reserved.
Slide 4: Corporate Profile
Corporate Profile Company Name KM Biologics Co., Ltd. Incorporated March 7, 2018 (Consolidated on July 2, 2018) Net Sales JPY 30.0 bn (Outlook for FYE March 2019) Operating Income JPY 3.5 bn (Outlook for FYE March 2019) Number of Employees 1,905 (as of July 2018) Main Business and Produc
Slide 5: Locations
Locations Koshi Production Center Kikuchi Research Center (103,000m2) (232,000m2) • Human vaccines production • R&D • Qualification test • Human vaccines production Headquarters & Kumamoto Production Center (147,000m2) ● ● ● ● Aso Production Center (118,000m2) Kumamoto pref. Administration, producti
Slide 6: KM Biologics' Technological Progress
KM Biologics’ Technological Progress We have produced outstanding innovations that have broken the mold in Japan and the world to prevent infection and treat disease. 2014 Launched Byclot, Japan’s first coagulation factor for hemophilia with inhibitors 2001 Launched OILVAX 7, Japan’s first 7-in-
Slide 7: At a Glance
At a Glance 20 First in the world / First Japanese-made 8 products /21 products products can be supplied only by us in Japan 8 orphan drugs 12 million vials of vaccines approved by the MHLW (Japan) shipped each year Exciting innovations developed by our Pandemic influenza vaccines for 160+ R&D staff
Slide 8: 2. Our Vision
2. Our Vision 8 ｜ 2018.12.10 ｜ Copyright © Meiji Holdings Co., Ltd. All rights reserved.
Slide 9: Our Vision
Our Vision We will explore potentials of biological science and contribute healthier lives of the people in the world as professionals in preventive and therapeutic areas. To earn the trust from society, customers and users, we will 1 Establish a corporate governance system 2 Restructure quality a
Slide 10: 1. Establish a corporate governance system
1. Establish a corporate governance system Improve impartial and transparent management Meiji Holdings • Secure compliance and a healthy business Shareholder Member of Corporate the Board Instruct, manage and supervise based on Auditor Meiji Group’s governance system Member of Member of the Board
Slide 11: 2. Restructure quality assurance and production management system
2. Restructure quality assurance and production management System Develop organizational infrastructure Board Meeting President • Clarify duties of general marketing compliance Management Meeting officer • Assign quality assurance staffs (QAS) at sites to Production Division Reliability Assurance
Slide 12: 3. Strengthen compliance administration and reform corporate culture
3. Strengthen compliance administration and reform corporate culture Compliance administration Establish Compliance Committee chaired by President Assign a compliance promotional officer and a Compliance Committee compliance practice leader at every workplace Conducting all transactions in compl
Slide 13: 3. Our Business Strategy
3. Our Business Strategy 13 ｜ 2018.12.10 ｜ Copyright © Meiji Holdings Co., Ltd. All rights reserved.
Slide 14: Our Business Strategy
Our Business Strategy Human pharmaceuticals 1 Strengthen business in Japan and expand overseas Veterinary pharmaceuticals 2 Expand business Biopharmaceuticals 3 Strengthen research and development 14 ｜ 2018.12.10 ｜ Copyright © Meiji Holdings Co., Ltd. All rights reserved.
Slide 15: 1. Human pharmaceuticals: Strengthen business in Japan and expand overseas
1. Human pharmaceuticals Strengthen business in Japan and expand overseas Human vaccines market Blood plasma products market (JPY bn) 1,995.4 2,000 1,000 1,936.5 The U.S. Demand continues to grow, but 1,888.2 1,900 900 1,823.8 there are issues 1,800 800 1,721.9 1,700 700 • Ig demand will increase
Slide 16: 1. Human pharmaceuticals: Our actions
1. Human pharmaceuticals Strengthen business in Japan and expand overseas Our actions Improve production and quality assurance systems to ensure stable production and supply with human vaccines and blood plasma products Improve usability/convenience and facilitate obtaining evidence Improve su
Slide 17: 2. Veterinary pharmaceuticals: Expand business
2. Veterinary pharmaceuticals Expand business Livestock vaccines market in Japan (JPY bn) 35 Market total The livestock vaccine market has been 30 leveling off 25 20 The three major vaccine manufacturers, 15 Swine including us, specialize in a different 10 Poultry sector Bovine 5 Overseas manu
Slide 18: 3. Biopharmaceuticals: Strengthen research and development
3. Biopharmaceuticals Strengthen research and development of biological drug R&D Pipeline (◆: compounds discovered in-house) FY3/19 FY3/20 FY3/21 Pentavalent vaccine against diphtheria, tetanus, pertussis, polio, Apply KD-370 and haemophilus influenza type b ◆ Phase III vaccines Human KD-382 Quadriv
Slide 19: 4. Outlook for FYE March 2019
4. Outlook for FYE March 2019 19 ｜ 2018.12.10 ｜ Copyright © Meiji Holdings Co., Ltd. All rights reserved.
Slide 20: Outlook for FYE March 2019 (Q2-Q4)
Outlook for FYE March 2019 (Q2-Q4) (JPY bn) Second Half Full Year First Half Results Plan Plan (as of Nov. 7) (as of Nov. 7) consolidated Net sales 9.9 20.0 30.0 Non- Operating income 1.6 1.8 3.5 (Note) Eliminations are recorded when calculate consolidation of KM Biologics. Sales and profit are di
Slide 21: 21
21